| ［1］ |
Moy AP, Murali M, Kroshinsky D, et al. Immunologic overlap of helper T⁃cell subtypes 17 and 22 in erythrodermic psoriasis and atopic dermatitis［J］. JAMA Dermatol, 2015,151（7）:753⁃760. doi: 10.1001/jamadermatol.2015.2.
|
| ［2］ |
Snoeck R, Andrei G, De Clercq E. Novel agents for the therapy of varicella⁃zoster virus infections［J］. Expert Opin Investig Drugs, 2000,9（8）:1743⁃1751. doi: 10.1517/13543784.9.8.1743.
|
| ［3］ |
Wagner JN, Leibetseder A, Troescher A, et al. Efficacy and safety of intravenous immunoglobulins for the treatment of viral encephalitis: a systematic literature review［J］. J Neurol, 2022,269（2）:712⁃724. doi: 10.1007/s00415⁃021⁃10494⁃w.
|
| ［4］ |
Mohammadzadeh I, Noei S, Babazadeh K, et al. Comparison of early and late intravenous gamma globulin treatment of Kawasaki disease on fever and cardiovascular complications［J］. Caspian J Intern Med, 2016,7（3）:211⁃216.
|
| ［5］ |
Wu KK, Lee MP, Lee EB, et al. Risk of herpes zoster with IL⁃17 inhibitor therapy for psoriasis and other inflammatory conditions［J］. J Dermatolog Treat, 2020,31（4）:359⁃365. doi: 10.1080/09546634.2019.1597246.
|
| ［6］ |
Lønnberg AS, Zachariae C, Skov L. Targeting of interleukin⁃17 in the treatment of psoriasis［J］. Clin Cosmet Investig Dermatol, 2014,7:251⁃259. doi: 10.2147/CCID.S67534.
|
| ［7］ |
Lo Y, Tsai TF. Updates on the Treatment of Erythrodermic Psoriasis［J］. Psoriasis （Auckl）, 2021,11:59⁃73. doi: 10.2147/PTT.S288345.
|
| ［8］ |
Mateu⁃Puchades A, Santos⁃Alarcón S, Martorell⁃Calatayud A, et al. Erythrodermic psoriasis and secukinumab: our clinical experience［J］. Dermatol Ther, 2018,31（4）:e12607. doi: 10.1111/dth.12607.
|
| ［9］ |
Lo Y, Tsai TF. Clinical experience of ixekizumab in the treatment of patients with history of chronic erythrodermic psoriasis who failed secukinumab: a case series［J］. Br J Dermatol, 2019,181（5）:1106⁃1107. doi: 10.1111/bjd.18174.
|
